EMBC
Embecta Corp.
EMBC offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over EMBC overall, supported by stronger fundamentals and lower modeled downside.
EMBC Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Strong | |
| Weak |
EMBC's profitability and cash flow are currently healthy, but its revenue and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
EMBC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.6x | $6.43 | — |
| Cheap | 4.2x | $6.18 | -3.9% |
| Current | 4.4x | $6.43 | — |
| Fair | 11x | $16.52 | +157% |
| Expensive | 15x | $22.04 | +243% |
Historical ranges are pointers, not guarantees.
EMBC has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
EMBC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect EMBC's earnings to grow, with its revenue and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over EMBC on the outlook, with more favorable revenue and profitability expectations.
EMBC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.81 | +23% |
| Q2 2026 | $1.47 | +3.5% |
| Q1 2026 | $1.89 | +112% |
| Q4 2025 | $2.36 | +138% |
| Q3 2025 | $1.62 | +21% |
| Q2 2025 | $1.42 | +17% |
| Q1 2025 | $0.89 | -27% |
| Q4 2024 | $0.99 | +3.1% |
| Q3 2024 | $1.34 | +9.8% |
EMBC's earnings per share have fallen from their peak: $1.47 over the past year, against $7.28 in late 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over EMBC on earnings, with more consistent year-over-year improvement.
EMBC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $271.7M | -8.1% |
| Q1 2026 | $221.8M | -14% |
| Q4 2025 | $261.2M | -0.3% |
| Q3 2025 | $264M | -7.7% |
| Q2 2025 | $295.5M | +8.4% |
| Q1 2025 | $259M | -9.8% |
| Q4 2024 | $261.9M | -5.6% |
| Q3 2024 | $286.1M | +1.5% |
EMBC's revenue is shrinking: $272M last quarter, down 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 18% | -14 points |
| Q1 2026 | 16% | -8.5 points |
| Q4 2025 | 32% | +21 points |
| Q3 2025 | 21% | +12 points |
| Q2 2025 | 32% | +11 points |
| Q1 2025 | 24% | +11 points |
| Q4 2024 | 11% | -5.4 points |
| Q3 2024 | 9.2% | 0 points |
EMBC's operating margin was 18% last quarter, down 14 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over EMBC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over EMBC on profitability, with a higher operating margin.
EMBC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $40.7M | -50% |
| Q1 2026 | $30.6M | -3.5% |
| Q4 2025 | $16.6M | +$23.4M |
| Q3 2025 | $76.7M | +188% |
| Q2 2025 | $80.8M | +$92.6M |
| Q1 2025 | $31.7M | +52% |
| Q4 2024 | -$6.8M | +$9M |
| Q3 2024 | $26.6M | +30% |
EMBC still generates free cash flow, though less than at its 2022 peak: $165M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
EMBC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -787K shares |
| 1 year | 0% | +17K shares |
| 3 years | +1.6% | +930K shares |
| 5 years | +2.7% | +1.5M shares |
EMBC has 59M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over EMBC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
EMBC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 4.6x | High |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 4.2x | High |
| Q2 2025 | 5.0x | High |
| Q1 2025 | 6.2x | High |
| Q4 2024 | 7.1x | High |
| Q3 2024 | 6.4x | High |
EMBC's net debt is about 4.6 years of its operating earnings (EBITDA), down from 5.0 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over EMBC on leverage, with a lower net debt burden relative to earnings.
EMBC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.7 | Neutral |
| Stochastic | 81.2 | Overbought |
EMBC's weekly RSI is 55 (neutral) and its Stochastic is 81 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
EMBC PE vs Healthcare Sector
| Metric | EMBC | Sector median | Relative |
|---|---|---|---|
| PE | 4.4x | 26x | 83% below |
| PE % | 19 | 43 | 24 pts below |
EMBC has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
EMBC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.14 | 4.7% above |
| 20 week MA | $5.08 | 27% above |
| 50 week MA | $7.14 | 9.9% below |
| 100 week MA | $10.4 | 38% below |
| 200 week MA | $14.4 | 55% below |
EMBC has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 55% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over EMBC on trend strength, trading above more of its moving averages.
EMBC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $43.0 | $27.5 | -36% |
| 2023 | $27.5 | $18.9 | -31% |
| 2024 | $18.9 | $20.7 | +9.4% |
| 2025 | $20.7 | $12.0 | -42% |
| 2026 YTD | $12.0 | $6.43 | -46% |
EMBC has finished lower in three of the last four years. It's down 46% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over EMBC on returns for 2026, with the stronger performance.